News & Updates

Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.

Heart surgery during the COVID-19 pandemic took a turn for the worse, with higher cost and poorer survival regardless of people’s socioeconomic status, according to US data.

In the treatment of Asian patients with ventilator-associated pneumonia (VAP), shortened antibiotic treatment duration guided by clinical response compares favourably with longer treatment durations used in usual care in terms of 60-day mortality and pneumonia recurrence, as shown in the open-label REGARD-VAP trial.

The addition of internal mammary nodal irradiation (IMNI) in the treatment of breast cancer leads to better overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and lower breast cancer mortality (BCM), reveals a study. In addition, patients with pN+ and medial/central tumour location achieved the best OS from IMNI.